← KIORA PHARMACEUTICALS INC (KPRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
KIORA PHARMACEUTICALS INC (KPRX)
Pharmaceutical Preparations · market cap $12M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Kiora Pharmaceuticals (KPRX) is a 12-employee, ~$10M market cap company with three Phase 2 programs in our data: KIO-104 (macular edema), KIO-301 (retinitis pigmentosa) and KIO-201, a CMHA-S crosslinked hyaluronic acid for persistent corneal epithelial defect. Cash is $7.1M against a ~$9.8M market cap, so the market is valuing the whole pipeline at only a few million dollars of enterprise value. The nearest catalyst is a KIO-104 Phase 2 event estimated for 2026-11-15, with KIO-301 estimated for 2027-08-15.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2026-11-15 (est.)Phase 2 · KIO-104imp 7/10
- 2027-08-15 (est.)Phase 2 · KIO-301imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KIO-104 | Phase 2 | Macular Edema |
| KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid (CMHA-S) | Phase 2 | Persistent Corneal Epithelial Defect |
| KIO-301 | Phase 2 | Retinitis Pigmentosa |
Price & technical context
3-month
-10.5%
6-month
-1.3%
12-month
-10.2%
52-wk range
$1.80–$2.86
vs 50-day MA
-9.7%
vs 200-day MA
-4.8%
Realized vol
54.7%
Max drawdown
-55.4%
Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KPRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.